| ID | 1342 |
| Name of the vaccine | ProDiax-23 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | DNA |
| Age | 70 to 75 years |
| Description of the vaccine | 23-valent Pneumococcal polysaccharide vaccine. |
| Name of the manufacturer | Korea University Guro Hospital |
| Name of the manufacturing country | Korea, Republic of |
| Year of manufacture | 2022 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Revaccination in old adults who received PPSV23 in previous 5-7 years. |
| Mechanism of action | IgG antibody titers against 13 pneumococcal serotypes. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | NA |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04875858 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|